GlaxoSmithKline (GSK) PT Set at GBX 1,620 by Cfra

Share on StockTwits

Cfra set a GBX 1,620 ($21.17) target price on GlaxoSmithKline (LON:GSK) in a research report report published on Tuesday morning. The brokerage currently has a neutral rating on the stock.

A number of other brokerages have also recently issued reports on GSK. JPMorgan Chase & Co. reissued a neutral rating and issued a GBX 1,600 ($20.91) target price on shares of GlaxoSmithKline in a research report on Tuesday, August 21st. Berenberg Bank reissued a buy rating and issued a GBX 1,790 ($23.39) target price on shares of GlaxoSmithKline in a research report on Thursday, August 23rd. Liberum Capital cut GlaxoSmithKline from a buy rating to a hold rating and upped their target price for the company from GBX 1,630 ($21.30) to GBX 1,700 ($22.21) in a research report on Thursday, August 30th. Jefferies Financial Group set a GBX 1,775 ($23.19) price objective on GlaxoSmithKline and gave the company a buy rating in a research note on Thursday, August 16th. Finally, Barclays reaffirmed an overweight rating on shares of GlaxoSmithKline in a research note on Friday, August 10th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and eight have given a buy rating to the stock. The company has a consensus rating of Hold and a consensus price target of GBX 1,512.99 ($19.77).

Shares of LON GSK opened at GBX 1,437.40 ($18.78) on Tuesday. GlaxoSmithKline has a 52-week low of GBX 1,235.20 ($16.14) and a 52-week high of GBX 1,724.50 ($22.53).

The business also recently disclosed a dividend, which will be paid on Thursday, January 10th. Shareholders of record on Thursday, November 15th will be paid a dividend of GBX 19 ($0.25) per share. This represents a yield of 1.26%. The ex-dividend date of this dividend is Thursday, November 15th.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

See Also: Stop Order

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.